Item Entry As previously disclosed, AIM ImmunoTech Inc. (the “ Company”) previously issued to Streeterville Capital, LLC (the “ Lender”) a Promissory Note in the original principal amount of $3,301,250.00 dated February 16, 2024 (the “ Note”) pursuant to a Note Purchase Agreement between the Company and the Lender. The Company and the Lender subsequently extended the maturity date of the Note to June 30, 2026. On May 18, 2026, the Company and the Lender entered into Amendment #2 to Promissory Note (the “ Amendment”), which amended the Note and further extended the maturity date of the Note until June 30, 2027. Pursuant to the Amendment, the Company agreed to pay the Lender an extension fee in the amount of $10,000.00 (the “ Extension Fee”), which Extension Fee was added to the outstanding balance of the Note. The Amendment also contains customary representations and warranties of the Company, as well as a representation and warranty of the Company that, as of the date of the Amendment, the outstanding balance of the Note, following the application of the Extension Fee, was $1,682,676.16. The foregoing is only a summary of the material terms of the Amendment and does not purport to be a complete description of the rights and obligations of the parties thereunder. Furthermore, the foregoing is qualified in its entirety by reference to the Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item Results The information set forth in the Press Release (as defined below) is incorporated herein by reference into this Item 2.02 to the extent required. The information, including Exhibit 99.1, referenced in this Item 2.02, is “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the “ Securities Act”), if and to the extent such subsequent filing specifically references the information herein as being incorporated by reference in such filing.

Item Creation The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference into this Item 2.03 to the extent required.

Item Regulation On May 19, 2026, the Company issued a press release (the “ Press Release”) related to the Amendment and other matters, a copy of which is furnished herewith as Exhibit 99.1. The information, including Exhibit 99.1, referenced in this Item 7.01, is “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act if and to the extent such subsequent filing specifically references the information herein as being incorporated by reference in such filing.

Item Financial Exhibit Description No. 10.1 Amendment #2 to Promissory Note, dated May 18, 2026, by and between Streeterville Capital, LLC and AIM ImmunoTech, Inc. 99.1 Press Release dated May 19, 2026. ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 104 Cover SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AIM Dated: By: /s/ Thomas